Download PDF
Neuropediatrics 2016; 47(03): 151-156
DOI: 10.1055/s-0036-1579633
Original Article
Georg Thieme Verlag KG Stuttgart · New York

Polymorphisms of Immunoglobulin G Fc Receptors in Pediatric Guillain–Barré Syndrome

Lobna A. Mansour
1   Department of Pediatrics, Faculty of Medicine, Cairo University, Cairo, Egypt
,
Marian Y. Girgis
1   Department of Pediatrics, Faculty of Medicine, Cairo University, Cairo, Egypt
,
Mohamed Abdulhay
2   Egypt Children Hospital, Cairo, Egypt
,
Ehab I. Abou ElEinein
3   Department of Rheumatology and Rehabilitation, Faculty of Medicine, Cairo University, Cairo, Egypt
,
Rabab ElHawary
4   Department of Clinical Pathology, Faculty of Medicine, Cairo University, Cairo, Egypt
,
Mariam Onsy F. Hanna
4   Department of Clinical Pathology, Faculty of Medicine, Cairo University, Cairo, Egypt
› Author Affiliations
Further Information

Publication History

10 October 2015

27 January 2016

Publication Date:
11 April 2016 (online)

    Permissions and Reprints

Abstract

Introduction Guillain–Barré syndrome (GBS) is an autoimmune peripheral neuropathy characterized by demyelination and axonal damage. Biallelic functional polymorphisms in the immunoglobulin G Fc receptors (FcγR)–FcγRIIA: H131/R131, FcγRIIIA: V158/F158, and FcγRIIIB: NA1/NA2 affect the affinity of the IgG–FcγR interaction, therefore, diseases such as GBS in which this interaction plays a critical role might be influenced by the polymorphisms.

Methods We evaluated the role of FcγR polymorphisms in susceptibility to GBS in Egyptian pediatric patients and the association of the variant alleles with neurophysiological types, severity, and outcome of the disease. A total of 50 patients with GBS and 50 controls were examined for FcγR polymorphisms by allele-specific polymerase chain reaction.

Results FcγRIIA H131 allele (p = < 0.0001; odds ratio [OR] = 4.78; 95% confidence interval [CI], 2.62–8.70) and FcγRIIA H/H131 genotype (p = < 0.0001 ; OR = 10.56; 95% CI, 3.59–31.06) were significantly increased in GBS patients while FcγRIIIA and FcγRIIIB allelic distributions were similar among patients and controls. The FcγR genotypes showed no association with neurophysiological types of GBS, severity or outcome of the disease.

Conclusions These findings reflect that FcγRIIA H131 allele may represent a risk marker for susceptibility to GBS.

Keywords

allele-specific polymerase chain reaction - Fc receptors - Guillain–Barré syndrome - immunoglobulin G - infection - polymorphism
 

  • References

  • 1 Hu W, Janke A, Ortler S , et al. Expression of CD28-related costimulatory molecule and its ligand in inflammatory neuropathies. Neurology 2007; 68 (4) 277-282
    CrossrefPubMedGoogle Scholar
  • 2 Zhang G, Bogdanova N, Gao T , et al. Fcγ receptor-mediated inflammation inhibits axon regeneration. PLoS ONE 2014; 9 (2) e88703
    CrossrefPubMedGoogle Scholar
  • 3 Winer JB. An update in Guillain-Barré syndrome. Autoimmune Dis 2014; 2014: 793024
    PubMedGoogle Scholar
  • 4 van Sorge NM, van den Berg LH, Geleijns K , et al. Anti-GM1 IgG antibodies induce leukocyte effector functions via Fcgamma receptors. Ann Neurol 2003; 53 (5) 570-579
    CrossrefPubMedGoogle Scholar
  • 5 Vedeler CA. Demonstration of Fc gamma receptors on human peripheral nerve fibres. J Neuroimmunol 1987; 15 (2) 207-216
    CrossrefPubMedGoogle Scholar
  • 6 Vedeler CA, Matre R, Kristoffersen EK, Ulvestad E. IgG Fc receptor heterogeneity in human peripheral nerves. Acta Neurol Scand 1991; 84 (3) 177-180
    CrossrefPubMedGoogle Scholar
  • 7 van der Pol W, van de Winkel JG. IgG receptor polymorphisms: risk factors for disease. Immunogenetics 1998; 48 (3) 222-232
    CrossrefPubMedGoogle Scholar
  • 8 van Sorge NM, van der Pol WL, van de Winkel JG. FcgammaR polymorphisms: Implications for function, disease susceptibility and immunotherapy. Tissue Antigens 2003; 61 (3) 189-202
    CrossrefPubMedGoogle Scholar
  • 9 Bruhns P, Iannascoli B, England P , et al. Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses. Blood 2009; 113 (16) 3716-3725
    CrossrefPubMedGoogle Scholar
  • 10 Wu J, Edberg JC, Redecha PB , et al. A novel polymorphism of FcgammaRIIIa (CD16) alters receptor function and predisposes to autoimmune disease. J Clin Invest 1997; 100 (5) 1059-1070
    CrossrefPubMedGoogle Scholar
  • 11 Bredius RG, Fijen CA, De Haas M , et al. Role of neutrophil Fc gamma RIIa (CD32) and Fc gamma RIIIb (CD16) polymorphic forms in phagocytosis of human IgG1- and IgG3-opsonized bacteria and erythrocytes. Immunology 1994; 83 (4) 624-630
    PubMedGoogle Scholar
  • 12 Vedeler CA, Raknes G, Myhr KM, Nyland H. IgG Fc-receptor polymorphisms in Guillain-Barré syndrome. Neurology 2000; 55 (5) 705-707
    CrossrefPubMedGoogle Scholar
  • 13 van Sorge NM, van der Pol WL, Jansen MD , et al. Severity of Guillain-Barré syndrome is associated with Fc gamma Receptor III polymorphisms. J Neuroimmunol 2005; 162 (1–2) 157-164
    CrossrefPubMedGoogle Scholar
  • 14 Sinha S, Prasad KN, Jain D, Nyati KK, Pradhan S, Agrawal S. Immunoglobulin IgG Fc-receptor polymorphisms and HLA class II molecules in Guillain-Barré syndrome. Acta Neurol Scand 2010; 122 (1) 21-26
    CrossrefPubMedGoogle Scholar
  • 15 Lehrnbecher T, Foster CB, Zhu S , et al. Variant genotypes of the low-affinity Fcgamma receptors in two control populations and a review of low-affinity Fcgamma receptor polymorphisms in control and disease populations. Blood 1999; 94 (12) 4220-4232
    PubMedGoogle Scholar
  • 16 Chen Y, Ma F, Zhang J, Chu X, Xu Y. Population incidence of Guillain-Barré syndrome in parts of China: three large populations in Jiangsu province, 2008-2010. Eur J Neurol 2014; 21 (1) 124-129
    CrossrefPubMedGoogle Scholar
  • 17 Goddard EA, Lastovica AJ, Argent AC. Campylobacter 0:41 isolation in Guillain-Barré syndrome. Arch Dis Child 1997; 76 (6) 526-528
    CrossrefPubMedGoogle Scholar
  • 18 Sanders LA, van de Winkel JG, Rijkers GT , et al. Fc gamma receptor IIa (CD32) heterogeneity in patients with recurrent bacterial respiratory tract infections. J Infect Dis 1994; 170 (4) 854-861
    CrossrefPubMedGoogle Scholar
  • 19 Asbury AK, Cornblath DR. Assessment of current diagnostic criteria for Guillain-Barré syndrome. Ann Neurol 1990; 27 (Suppl): S21-S24
    CrossrefPubMedGoogle Scholar
  • 20 Hughes RA, Newsom-Davis JM, Perkin GD, Pierce JM. Controlled trial prednisolone in acute polyneuropathy. Lancet 1978; 2 (8093) 750-753
    PubMedGoogle Scholar
  • 21 Hadden RD, Cornblath DR, Hughes RA , et al; Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. Electrophysiological classification of Guillain-Barré syndrome: clinical associations and outcome. Ann Neurol 1998; 44 (5) 780-788
    CrossrefPubMedGoogle Scholar
  • 22 Carrington CV, Norman PJ, Vaughan RW , et al. Analysis of Fc gamma receptor II (CD32) polymorphism in populations of African and South Asian ancestry reveals east-west geographic gradients of allele frequencies. Eur J Immunogenet 2003; 30 (5) 375-379
    CrossrefPubMedGoogle Scholar
  • 23 Dall'Ozzo S, Andres C, Bardos P, Watier H, Thibault G. Rapid single-step FCGR3A genotyping based on SYBR Green I fluorescence in real-time multiplex allele-specific PCR. J Immunol Methods 2003; 277 (1–2) 185-192
    CrossrefPubMedGoogle Scholar
  • 24 Xu G, He Q, Shou Z , et al. Association of Fc gamma receptor IIIB polymorphism with renal-allograft in Chinese. Transpl Immunol 2007; 18 (1) 28-31
    CrossrefPubMedGoogle Scholar
  • 25 Yamamoto K, Kobayashi T, Sugita N, Tai H, Yoshie H. The FcgammaRIIa polymorphism influences production of interleukin-1 by mononuclear cells. Int J Immunogenet 2007; 34 (5) 369-372
    CrossrefPubMedGoogle Scholar
  • 26 Yuki N, Ichihashi Y, Taki T. Subclass of IgG antibody to GM1 epitope-bearing lipopolysaccharide of Campylobacter jejuni in patients with Guillain-Barré syndrome. J Neuroimmunol 1995; 60 (1–2) 161-164
    CrossrefPubMedGoogle Scholar
  • 27 He L, Zhang G, Liu W, Gao T, Sheikh KA. Anti-ganglioside antibodies induce nodal and axonal injury via Fcγ receptor-mediated inflammation. J Neurosci 2015; 35 (17) 6770-6785
    CrossrefPubMedGoogle Scholar
  • 28 Allos BM. Association between Campylobacter infection and Guillain-Barré syndrome. J Infect Dis 1997; 176 (Suppl. 02) S125-S128
    CrossrefPubMedGoogle Scholar
  • 29 Jacobs BC, Rothbarth PH, van der Meché FG , et al. The spectrum of antecedent infections in Guillain-Barré syndrome: a case-control study. Neurology 1998; 51 (4) 1110-1115
    CrossrefPubMedGoogle Scholar
  • 30 Vedeler CA, Wik E, Nyland H. The long-term prognosis of Guillain-Barré syndrome. Evaluation of prognostic factors including plasma exchange. Acta Neurol Scand 1997; 95 (5) 298-302
    CrossrefPubMedGoogle Scholar
  • 31 Hughes RA, Rees JH. Clinical and epidemiologic features of Guillain-Barré syndrome. J Infect Dis 1997; 176 (Suppl. 02) S92-S98
    CrossrefPubMedGoogle Scholar
  • 32 Kimberly RP, Edberg JC, Merriam LT, Clarkson SB, Unkeless JC, Taylor RP. In vivo handling of soluble complement fixing Ab/dsDNA immune complexes in chimpanzees. J Clin Invest 1989; 84 (3) 962-970
    CrossrefPubMedGoogle Scholar
  • 33 Fokkink WJ, Selman MH, Dortland JR , et al. IgG Fc N-glycosylation in Guillain-Barré syndrome treated with immunoglobulins. J Proteome Res 2014; 13 (3) 1722-1730
    CrossrefPubMedGoogle Scholar
  • 34 Berger M, McCallus DE, Lin CS. Rapid and reversible responses to IVIG in autoimmune neuromuscular diseases suggest mechanisms of action involving competition with functionally important autoantibodies. J Peripher Nerv Syst 2013; 18 (4) 275-296
    CrossrefPubMedGoogle Scholar